Dominika A Kalkowska

InstitutionKid Risk
AddressColumbus
Ohio
United States
vCardDownload vCard
    Publication Timeline
    COVID-19 publications
    Bar chart showing 9 Covid-19 publications, with a maximum of 3 publications in May 2021
    All Publications
    Bar chart showing 22 publications over 8 distinct years, with a maximum of 7 publications in 2021
    These graphs show COVID-19 publications by month since August 2019 and all publications written by authors of COVID-19 publications over the past 30 years.

    To see the data from both graphs as text, click here.
    Publication Field Summary
    This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.
    Publication List
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
    Sort By:     Newest   |   Oldest   |   Most Cited   |   Most Discussed
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Kalkowska DA, Pallansch MA, Cochi SL, Thompson KM. Updated Characterization of Poliovirus Transmission in Pakistan and Afghanistan and the Impacts of Different Outbreak Response Vaccine Options. J Infect Dis. 2021 11 16; 224(9):1529-1538. PMID: 33885734.
      Citations: 1     Fields:    Translation:HumansCellsPHPublic Health
    2. Kalkowska DA, Pallansch MA, Wassilak SGF, Cochi SL, Thompson KM. Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response. Vaccine. 2021 May 13. PMID: 33994237.
      Citations:    Fields:    
    3. Thompson KM, Kalkowska DA, Badizadegan K. Hypothetical emergence of poliovirus in 2020: part 2. exploration of the potential role of vaccines in control and eradication. Expert Rev Vaccines. 2021 04; 20(4):449-460. PMID: 33599178.
      Citations:    Fields:    Translation:HumansCellsPHPublic Health
    4. Thompson KM, Kalkowska DA, Badizadegan K. Hypothetical emergence of poliovirus in 2020: part 1. Consequences of policy decisions to respond using nonpharmaceutical interventions. Expert Rev Vaccines. 2021 04; 20(4):465-481. PMID: 33624568.
      Citations:    Fields:    Translation:HumansCellsPHPublic Health
    5. Kalkowska DA, Voorman A, Pallansch MA, Wassilak SGF, Cochi SL, Badizadegan K, Thompson KM. The impact of disruptions caused by the COVID-19 pandemic on global polio eradication. Vaccine. 2021 Apr 27. PMID: 33962838.
      Citations: 4     Fields:    
    6. Thompson KM, Kalkowska DA, Badizadegan K. No Role for Reintroducing OPV into the United States with Respect to Controlling COVID-19 [Response to the letter to the Editor by Chumakov et al.]. Risk Anal. 2021 02; 41(2):389-392. PMID: 33590518.
      Citations:    Fields:    Translation:Humans
    7. Thompson KM, Kalkowska DA. An Updated Economic Analysis of the Global Polio Eradication Initiative. Risk Anal. 2021 02; 41(2):393-406. PMID: 33590521.
      Citations: 6     Fields:    Translation:HumansPHPublic Health
    8. Thompson KM, Kalkowska DA, Badizadegan K. A Health Economic Analysis for Oral Poliovirus Vaccine to Prevent COVID-19 in the United States. Risk Anal. 2021 02; 41(2):376-386. PMID: 33084153.
      Citations: 6     Fields:    Translation:HumansPHPublic Health
    9. Kalkowska DA, Thompson KM. Expected Implications of Globally Coordinated Cessation of Serotype 3 Oral Poliovirus Vaccine (OPV) Before Serotype 1 OPV. Risk Anal. 2021 02; 41(2):312-319. PMID: 32936466.
      Citations: 3     Fields:    Translation:HumansCellsPHPublic Health